All investors in Innovent Biologics, Inc. (HKG:1801) should be aware of the most powerful group of shareholders. And the group with the largest piece of the pie is the institution with 47% ownership. In other words, the group stands to gain the most if the share price rises (or suffer the most loss if it falls).
After a year of 55% losses, last week’s 6.2% rally will be welcomed by institutional investors as a sign of an uptrend in returns.
Let’s take a closer look at each type of Innovent Biologics owner, starting with the chart below.
Our analysis 1801 may be underrated.
What does institutional ownership tell us about Innovent’s biologics?
Institutional investors typically compare their returns to those of commonly followed indices. As such, they typically look to acquire large companies included in the relevant benchmark index.
You can see that Innovent Biologics has institutional investors. They own a significant portion of the company’s stock. This means that analysts working for these institutions have seen the stock and liked it. But, like everyone else, they can be wrong.If multiple institutions change their views on a stock at the same time, the stock can fall rapidly. Therefore, it’s worth taking a look at Innovent Biologics’ earnings history below. Of course, the future really matters.
Hedge funds don’t own much of Innovent Biologics. The company’s largest shareholder is Fidelity International Ltd, who owns 9.1%. De-Chao Yu is the second largest shareholder, owning his 6.9% of the common stock, and Capital Research and Management Company owns approximately 6.0% of the company’s shares. His De-Chao Yu, the second largest shareholder, also happens to hold the title of CEO.
Looking at the shareholder register, we can see that 50% of the ownership is controlled by the top 15 shareholders.
It makes sense to study institutional investor data for companies, but it also makes sense to study analyst sentiment to get an idea of where the wind is heading. Quite a few analysts cover stocks, so it’s very easy to look up forecast growth.
Insider Ownership of Innovent Biologics
While the precise definition of an insider can be subjective, we believe that most directors are insiders. Management finally answers to the board. However, it is not uncommon for managers to be members of the board of directors, especially for founders and CEOs.
Insider ownership is positive if leadership shows that they think like true owners of the company. However, high insider ownership can also give greater power to smaller groups within the company. This can be negative in some situations.
Our latest data indicates that insiders own partial shares of Innovent Biologics, Inc. Most people would see this as a true positive. If you want to learn more about insider collaboration, click here to see if insiders are buying or selling.
The general public, including private investors, own 39% of the company’s shares, so they can’t simply ignore it. Ownership of this magnitude may not be enough to move policy decisions in their favor, but they can still collectively influence company policy.
Private equity ownership
With a 5.8% ownership interest, the private equity firm is positioned to play a role in shaping corporate strategy focused on value creation. Private equity can be long-lived, but generally speaking, private equity has a short investment horizon and, as the name suggests, does not invest in public companies very often. After some time, they may consider selling the capital and relocating it elsewhere.
I think it will be very interesting to see who exactly owns the company. But for true insight, other information must also be considered. for example, One Warning Sign from Innovent Biologics What you should know.
If you’re like me, think about whether this company will grow or shrink. Luckily, you can check out this free report that shows analysts’ predictions for the future.
Note: The numbers in this article are calculated using the last 12 months of data. This refers to his 12-month period ending on the last day of the month in which the financial statements are dated. This may not match the annual report figures for the full year.
Valuation is complicated, but we’re here to help make it simple.
find out if Innovent Biologics You may be overestimated or underestimated by checking out our comprehensive analysis including: Fair value estimates, risks and warnings, dividends, insider trading and financial health.
View Free Analysis
Do you have feedback on this article? What interests you? contact directly with us. Or send an email to our editorial team (at) Simplywallst.com.
This article by Simply Wall St is general in nature. We provide comments based on historical data and analyst projections using only unbiased methodologies and our articles are not intended as financial advice. It is not a recommendation to buy or sell stocks and does not take into account your objectives or financial situation. We aim to deliver long-term focused analysis based on fundamental data. Please note that our analysis may not take into account the latest price-sensitive company announcements or qualitative materials. Is not …